Mooney, C.
McKiernan, P. J. http://orcid.org/0000-0001-6756-0799
Raoof, R.
Henshall, D. C.
Linnane, B.
McNally, P.
Glasgow, A. M. A.
Greene, C. M.
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (MSCA-IF award 707771)
Vertex Pharmaceuticals (Innovation Award 2018)
Article History
Received: 30 August 2019
Accepted: 21 December 2019
First Online: 24 January 2020
Competing interests
: P.J.M.c.K., R.R., B.L. and P.M.c.N. report no conflicts of interest. C.M., A.M.A.G. and C.M.G. have no relevant conflicts of interest to disclose other than the receipt of funding from the agencies named above to carry out the current work. In addition to the funding named above, D.C.H. reports grants from Science Foundation Ireland and Framework Programme Seven (EU) during the conduct of the study, as well as a patent entitled “Inhibition of microRNA-134 for the treatment of seizure-related disorders and neurologic injuries issued”.